IOVA241227C4500
- 0.00
- 0.000.00%
Iovance Biotherapeutics Newsroom
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Express News | Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
After a Year of 0.6% Returns, Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price Drop Last Week May Have Less of an Impact on Institutional Investors
Peering Into Iovance Biotherapeutics's Recent Short Interest
Is Iovance Biotherapeutics Stock a Millionaire Maker?
Press Release: Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
Express News | Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.d., Ph.d. to Chief Regulatory Officer
Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Share Price Not Quite Adding Up
Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back
Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks With Biggest Upside Potential According to Analysts
Iovance Biotherapeutics Optimizes Headquarters for Cost Efficiency
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
JMP Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $23
Iovance Biotherapeutics: Promising Growth and Expansion in Cancer Treatment Fuels Buy Rating
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $21 to $32
Express News | Iovance Biotherapeutics Inc : Stifel Cuts Target Price to $21 From $23
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript Summary